NCT03868423: Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers

NCT03868423
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: ALK, ROS
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have activating genomic alterations in ALK or ROS1 (mutations, fusions or amplifications) & must have progressed on any previous therapy including crizotinib & other ALK inhibitors; Patients with de novo metastatic disease who have not received any treatment are also eligible
Exclusions: Patients with symptomatic CNS metastases that are neurologically unstable or require treatment
https://ClinicalTrials.gov/show/NCT03868423

Comments are closed.

Up ↑